Inhibitex (NASDAQ: INHX) was downgraded by research analysts at William Blair from an “outperform” rating to a “market perform” rating in a report issued on Monday.
Separately, analysts at Canaccord Genuity downgraded shares of Inhibitex from a “buy” rating to a “hold” rating in a research note to investors on Thursday. They now have a $26.00 price target on the stock. Analysts at Deutsche Bank (NYSE: DB) downgraded shares of Inhibitex from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, January 24th. They now have a $26.00 price target on the stock, up previously from $15.00.
Inhibitex, Inc.is a biopharmaceutical company focused on the development of differentiated anti-infective products to prevent or treat serious infections. The Company’s research and development efforts are focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by Hepatitis C Virus (HCV) and herpes zoster, which is caused by the varicella zoster virus (VZV). The Company’s anti-infective product candidates include INX-189, HCV Nucleotide Polymerase Inhibitors, FV-100, Staphylococcal Vaccines and Aurexis.
Inhibitex opened at 25.10 on Monday. Inhibitex has a 1-year low of $2.15 and a 1-year high of $25.15. The stock has a 50-day moving average of $16.96 and a 200-day moving average of $8.03. The company’s market cap is $1.965 billion.